Skip to main content
Premium Trial:

Request an Annual Quote

Investment Banks Upgrade Illumina, Affy Stock in Wake of Judge's Decision

NEW YORK (GenomeWeb News) - Investment firm Caris & Company upgraded Illumina's stock to "Buy" from "Above Average" today.
 
The broker cited "removal of Markman ruling overhang" as the reason behind the upgrade.
 
Separately today, investment bank UBS lifted Affymetrix' price target to $20 from $18.
 
As GenomeWeb News reported this morning, a district court judge issued a Markman order to interpret 15 key terms in Affymetrix’ patent infringement case against Illumina.
 
Shares in Affy were down 4.51 percent, or $1, at $21.13 in mid-afternoon trading while shares in Illumina were up 3.67 percent, or $1.17, at 32.98.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.